BSD Medical Reports Publication of Hyperthermia Article by Journal of the National Cancer Institute

BSD Medical Corp. (NASDAQ: BSDM) reports publication of a news article by the Journal of the National Cancer Institute on the evolving role of hyperthermia in cancer therapy titled, “International Study of Hyperthermia Spurs Hope in U.S.” (J. Natl. Cancer Inst. 2010 102: 79-81; doi:10.1093/jnci/djp530). The article reviewed the history of hyperthermia in cancer therapy, including the challenges faced by hyperthermia advocates and the progress that has been made in addressing these challenges. The article stated that, “Successful use of targeted heat therapy with chemotherapy in treatment of soft-tissue sarcoma has given U.S. advocates of local hyperthermia new hope that the treatment they so believe in will now be taken seriously.”

Cerus Corporation Reports Positive Outcome in European Study of 7-Day INTERCEPT Platelets

Cerus Corporation (NASDAQ: CERS) announced today that INTERCEPT-treated platelet components were found to be effective for patient support following extended six and seven day storage in a clinical study conducted at four sites in Europe. These data further confirm the safety and therapeutic efficacy of platelets treated with the INTERCEPT Blood System, a pathogen inactivation treatment designed to protect against transfusion-transmitted diseases.

"This study shows that INTERCEPT platelets remain therapeutically effective even after six or seven days of storage," said Dr. Miguel Lozano of the Hospital Clinic in Barcelona, Spain, the study's lead investigator. "The ability to store platelets longer than five days can be critical to maintaining an adequate supply, but extended storage of conventional platelets creates an increased risk of transfusion-transmitted bacterial infection.

Zargis Cardioscan Cleared for Sale in Canada

Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp. (Nasdaq: SPDE), today announced that Health Canada, the Canadian equivalent of the U.S. FDA, has cleared the Zargis Cardioscan(TM) device for sale in Canada.

The Cardioscan heart sound analysis software connects wirelessly to a Bluetooth®-enabled electronic stethoscope and is designed to help physicians analyze cardiac sounds for the identification and classification of suspected heart murmurs. As previously announced, Zargis Medical was a co-recipient of Popular Science magazine's 2009 "Innovation of the Year" award for Cardioscan.

With 62,000 physicians treating a population of nearly 34 million people, Canada represents a significant market for Zargis. Furthermore, Cardioscan's optional telemedicine capabilities are well suited for the Canadian healthcare system, which has embraced telemedicine as a core initiative.

FDA Grants 510(k) Marketing Clearance for Cytori's PureGraft(TM) System; First & Only Device on Market for Aesthetic Body Contouring using Autologous Fat Grafts

The FDA has granted Cytori Therapeutics (NASDAQ: CYTX) 510(k) marketing clearance for its PureGraft(TM) System. Cytori will now launch the first and only device in the United States cleared for aesthetic body contouring using autologous fat. PureGraft(TM) allows a patient's own fat tissue to rapidly be prepared in approximately 15 minutes for re-injection back into the same patient for aesthetic contouring.

PureGraft(TM) is able to prepare both small and large volumes of fat grafting tissue ranging from 50 mL to 250 mL. Puregraft(TM) maintains sterility while optimizing the yield of tissue to be grafted, which provides significant utility to physicians. In contrast to traditional methods of graft preparation, PureGraft(TM) washes the graft and drains the tumescent fluid, free lipid and debris in a closed sterile system, allowing for a cleaner graft in less time than it would take to prepare a comparable volume of graft tissue traditionally.